Farmakoterapia w Psychiatrii i Neurologii

Full text

1/2021 vol. 37
Review paper

Two in one: simultaneous use of two long-acting antipsychotics in schizophrenia

Marek Jarema 1
  1. 3rd Department of Psychiatry, Institute of Psychiatry and Neurology in Warsaw, Poland
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 45–51
Data publikacji online: 2021/11/17
Article file
03R_IPiN_FARM_2021-1C.pdf
  1. Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, Santambrogio J. Long-acting injectable antipyschotics in schizophrenia: literature review and practical perspective with focus on aripiprazole once-monthly. Adv Ther. 2017; 34: 1036-1048.
  2. Ceylan MF, Erdogan B, Hesapcioglu ST. Effectiveness, adverse effects and drug compliance of Long-acting Injectable risperidone in children and adolescents. Clin Drug Investing 2017; 37: 947-956.
  3. Diefendorfer LA. When should you consider combining 2 long-acting injectable antipsychotics? Curr Psychiatry 2017; 16: 42-46.
  4. Jarema M (red.). Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2015.
  5. Jarema M, Bieńkowski P, Heitzman J, Parnowski T, Rybakowski J. Palmitynian paliperidonu: skuteczność, bezpieczeństwo stosowania i miejsce w leczeniu schizofrenii. Psychiatr. Pol. 2017, 51: 7-21.
  6. Jarema M, Wichniak A. Long-acting aripiprazole in the treatment of schizophrenia; practical aspects. Pharmacol. Psychiatry Neurol. 2017, 32: 145-165.
  7. Jarema M, Wichniak A, Dudek D, Samochowiec J, Bieńkowski P, Rybakowski J. Second-generation long-acting antipsychotics: when to use and how. Farmakother. Psychiatr. Neurol. 2015; 31: 57-66 (a).
  8. Jarema M, Wichniak A, Dudek A, Samochowiec J, Bieńkowski P, Rybakowski J. Wskazówki do stosowania leków przeciwpsychotycznych II generacji o przedłużonym działaniu. Psychiatr. Pol. 2015; 49: 225-242 (b).
  9. Ladds B, Cosme R, Rivera F. Concurrent use of two depot antipsychotic medications in schizophrenia. Internet J Psychiatry 2019.
  10. Malinowska-Kubiak M, Permoda-Osip A. Zastosowanie trzech leków przeciwpsychotycznych w iniekcjach o przedłużonym działaniu u pacjentka z objawami psychotycznymi w przebiegu choroby choroby Huntingtona – opis przypadku. Farm Psych Neurol 2017; 33: 67-75.
  11. Mathew C, Venkatesh SA, Tirupati S. Use of two long-acting injectable antipsychotics for treatment-resistant schizophrenia. Aust N Z J Psychiatry 2018; 52: 1098-1099.
  12. McInnis P, Kasinathan J. Combination long-acting injectable (LAI) antipsychotic medication in adolescents with severe psychosis and aggression: a case series. Austr Psychiatry 2019; 27: 160-267.
  13. Meltzer HY, Alphs L, Green AI, Altamura AC, Anland R, Bertoldi A i wsp. Clozapine treatment for suicidality in schizophrenia – International Suicide Prevention Trial. Arch Gen Psychiatry 2003; 60: 82-91.
  14. Pacchiarotti I, Tiihonen J, Kotzalidis GD, Verdolini N, Murru A, Goikolea JM i. wsp.: Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychophamacol 2019; 29: 457-470.
  15. Pompili M, Orsolini L, Lamis DA, Goldsmith DR, Nardella A, Falcone G i wsp. Suicide prevention in schizophrenia: do long-acting injectable antipsychotics (LAIs) have a role? CNS Neurol Disord Drug Targets 2017; 16: 454-462.
  16. Sengul C, Kalkanci O, Simsek D, Herken H. Maintenance electroconvulsive therapy combined with long-acting risperidone in the treatment of resistant bipolar affective disorder. Journal ECT 2009; 25: 282.
SUBMIT YOUR PAPER
Share
without publication fees
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications